C.R. Bard, Inc. (NYSE:BCR) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Several other equities research analysts also recently weighed in on the stock. Jefferies Group LLC reissued a “hold” rating on shares of C.R. Bard in a research report on Thursday. Zacks Investment Research downgraded shares of C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, BMO Capital Markets reissued a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a research report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $285.67.

C.R. Bard (NYSE BCR) opened at 318.58 on Friday. The stock has a 50 day moving average price of $317.93 and a 200-day moving average price of $279.50. The stock has a market cap of $23.15 billion, a P/E ratio of 41.82 and a beta of 0.59. C.R. Bard has a 52 week low of $203.63 and a 52 week high of $323.27.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.84 by $0.08. The company had revenue of $979.70 million during the quarter, compared to the consensus estimate of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.54 earnings per share. On average, equities analysts anticipate that C.R. Bard will post $11.79 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.dailypolitical.com/2017/08/07/c-r-bard-inc-bcr-stock-rating-lowered-by-bidaskclub.html.

A number of large investors have recently modified their holdings of BCR. Fundsmith LLP boosted its stake in shares of C.R. Bard by 2.1% in the first quarter. Fundsmith LLP now owns 2,553,141 shares of the medical instruments supplier’s stock valued at $633,996,000 after buying an additional 52,272 shares in the last quarter. Creative Planning boosted its stake in shares of C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock valued at $1,068,000 after buying an additional 29 shares in the last quarter. Granite Investment Advisors LLC boosted its stake in shares of C.R. Bard by 14.3% in the first quarter. Granite Investment Advisors LLC now owns 33,276 shares of the medical instruments supplier’s stock valued at $8,270,000 after buying an additional 4,159 shares in the last quarter. Buffington Mohr McNeal boosted its stake in shares of C.R. Bard by 14.1% in the first quarter. Buffington Mohr McNeal now owns 7,545 shares of the medical instruments supplier’s stock valued at $1,875,000 after buying an additional 930 shares in the last quarter. Finally, Huntington National Bank boosted its stake in shares of C.R. Bard by 8.4% in the first quarter. Huntington National Bank now owns 16,411 shares of the medical instruments supplier’s stock valued at $4,079,000 after buying an additional 1,278 shares in the last quarter. Institutional investors own 85.32% of the company’s stock.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.